Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TNFSF18 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFSF18 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TNFSF18 Products |
| Gene Delivery | TNFSF18 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TNFSF18 Products |
| Benchmark Ab | Anti-TNFSF18 (Sequence of clinical benchmark) Recombinant positive control. |
View TNFSF18 Products |
| Validator | TNFSF18 siRNA Set For knockdown verification. |
View TNFSF18 Products |
| Related Target A | TNFRSF18 Cognate receptor (GITR) essential for receptor-ligand binding kinetics and activation assays. |
View TNFRSF18 Products |
| Related Target B | CD274 PD-L1 checkpoint. Synergistic target commonly combined with TNFSF18/TNFRSF18 pathway modulators. |
View CD274 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native Trimeric Conformation | HEK293 Expressed (Native Glycosylation) to support natural trimer assembly. |
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) available |
| False Positives | Validated siRNA included for specificity checks |
Live TNFSF18 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the TNFSF18 (GITRL) / TNFRSF18 (GITR) pathway is a crucial frontier in cancer immunotherapy and autoimmune modulation. As a key co-stimulatory pathway, TNFSF18 interacts with TNFRSF18 on T cells and regulatory T cells (Tregs) to enhance effector T cell proliferation and suppress Treg-mediated inhibition.
The race for TNFSF18 therapeutics is intensifying, with major players shifting focus from traditional monomeric agonist mAbs to multimeric ligand fusions and bispecific platforms. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-localized activation to maximize co-stimulation while minimizing systemic immune-related adverse events.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Multimeric Fusion Protein | AstraZeneca, MedImmune | Advanced Solid Tumors | Oligomerization Validation (Need native, high-purity ECD-Fc proteins) |
| Bispecific Antibody (e.g., PD-L1 x GITR) | Incyte, F-star Therapeutics | Immunotherapy Resistant Cancers | Dual-binding Affinity Profiling (Need sequence-verified TNFRSF18 and CD274 antigens) |
| Agonistic Monoclonal Antibody | Leap Therapeutics, Novartis, Merck | Melanoma, Colorectal Cancer | Receptor-Ligand Blocking Assay (Need high-purity TNFSF18 and benchmark controls) |